Showing results (1-10 of 29) with videos related to
Sort By:
Pageof 3
Expert Opinion on Pharmacotherapy|October 6, 2006
Breast cancer expression profiling: the impact of microarray testing on clinical decision makingOlga Modlich, Hans-Bernd Prisack, Hans BojarCancer Genetics and Cytogenetics|December 31, 2002
Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer familiesVera Balz, Hans Bernd Prisack, Henning Bier, et al.The Breast Journal|May 12, 2001
The Estrogen Receptor Paradox in Breast Cancer: Association of High Receptor Concentrations with Reduced Overall SurvivalKerstin Struse, Werner Audretsch, Mahdi Rezai, et al.Journal of Translational Medicine|August 11, 2005
Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signaturesOlga Modlich, Hans-Bernd Prisack, Marc Munnes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer diseaseOlga Modlich, Hans-Bernd Prisack, Marc Munnes, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 27, 2002
Gene expression profiling of advanced head and neck squamous cell carcinomas and two squamous cell carcinoma cell lines under radio/chemotherapy using cDNA arraysKarl Axel Hartmann, Olga Modlich, Hans Bernd Prisack, et al.Integrative Cancer Therapies|September 9, 2018
Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2Ralf Kleef, Ralph Moss, A Marcell Szasz, et al.Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|May 25, 2010
Retrospective study of neoadjuvant versus adjuvant radiochemotherapy in locally advanced noninflammatory breast cancer : survival advantage in cT2 category by neoadjuvant radiochemotherapyStephan Ludwig Roth, Werner Audretsch, Hans Bojar, et al.Cancer|March 31, 2007
Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcomeChristopher Kramer, Kai Klasmeyer, Hans Bojar, et al.Anticancer Research|December 13, 2005
Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapyHans-Bernd Prisack, Christiaan Karreman, Olga Modlich, et al.Pageof 3